Cirrhosis Plasma
Cirrhosis Plasma from IRB-consented donors with clinically confirmed cirrhosis. Supports non-invasive fibrosis and portal hypertension biomarker work, coagulation studies, and proteomic profiling stratified by etiology, Child-Pugh class, and MELD score.
Cirrhosis Plasma for Fibrotic Liver Disease Research
Cirrhosis Plasma is collected from IRB-consented donors clinically diagnosed with cirrhosis and processed within one day of collection to preserve key analytes such as cytokines, proteins, and metabolites. Cirrhosis is the advanced stage of chronic hepatic fibrosis: sustained liver injury drives extracellular matrix deposition, architectural distortion with regenerative nodules, and portal hypertension. This human plasma supports research on fibrosis staging, portal hypertension, hepatic synthetic function, and non-invasive biomarker development.
Cirrhosis Biology and Why Plasma
- Fibrogenesis: hepatic stellate cell activation and myofibroblast transformation drive collagen and matrix deposition. Plasma carries matrix turnover markers including PRO-C3, hyaluronic acid, and TIMP-1, alongside metalloproteinase activity.
- Portal hypertension: increased intrahepatic resistance combined with splanchnic vasodilation produces varices, ascites, and hypersplenism, with downstream changes in platelet count and circulating vasoactive mediators.
- Loss of synthetic and clearance function: falling albumin, prolonged coagulation times, and rising bilirubin underpin Child-Pugh and MELD scoring, making plasma a natural matrix for functional staging research.
- Rebalanced hemostasis: cirrhosis reduces synthesis of both procoagulant and anticoagulant factors, and citrated plasma is the standard specimen for coagulation factor, thrombin generation, and von Willebrand factor studies.
- Systemic inflammation and the gut-liver axis: bacterial translocation and endotoxemia elevate circulating cytokines and contribute to the immune dysfunction associated with decompensation.
- Acellular matrix: plasma suits proteomic, metabolomic, cell-free DNA, and immunoassay work on soluble analytes. Cell-based assays are supported by our cirrhosis PBMC, leukopak, and whole blood products.
Donor Stratification Available
- Etiology: chronic hepatitis B or C, alcohol-related liver disease, MASH/NAFLD-related, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, or cryptogenic — autoimmune and cholestatic causes are one group among several, not the general case
- Child-Pugh class A, B, or C
- MELD or MELD-Na score band where documented
- Compensated versus decompensated disease
- Decompensation events: ascites, variceal bleeding, or hepatic encephalopathy
- Hepatocellular carcinoma status, and transplant waitlist or post-transplant status
- Antiviral treatment history and sustained virologic response status in viral etiologies
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed cirrhosis donors
- Processed within one day of collection
- Choice of anticoagulant (EDTA, sodium citrate, or heparin) on request
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
De-identified Donor Data
- Verified cirrhosis diagnosis with documented etiology
- Demographic data: age, sex assigned at birth, race/ethnicity
- Child-Pugh class and MELD score where available
- Donor-reported medications, allergies, and comorbidities
- Additional cirrhosis-specific metadata available on request
Applications
- Non-invasive fibrosis biomarker discovery and validation
- Matrix turnover and fibrogenesis marker panels
- Proteomic and metabolomic profiling across Child-Pugh and MELD strata
- Coagulation and hemostasis research in citrated plasma
- Cytokine and systemic inflammation profiling in decompensation
- Etiology-stratified comparisons across viral, alcohol-related, MASH, and cholestatic disease
- Cell-free DNA and extracellular vesicle studies
- Antifibrotic drug development and pharmacodynamic biomarker work
Other Cirrhosis Specimen Types
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Cirrhosis plasma is available in standard and custom volumes. For pricing, current availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse other conditions and live stock status, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.